Compare Unichem Lab with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

UNICHEM LAB vs STRIDES PHARMA SCIENCE - Comparison Results

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    UNICHEM LAB STRIDES PHARMA SCIENCE UNICHEM LAB/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 57.2 13.8 414.7% View Chart
P/BV x 0.6 0.8 75.4% View Chart
Dividend Yield % 2.3 0.6 377.8%  

Financials

 UNICHEM LAB   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    UNICHEM LAB
Mar-19
STRIDES PHARMA SCIENCE
Mar-18
UNICHEM LAB/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs2921,147 25.5%   
Low Rs182642 28.3%   
Sales per share (Unadj.) Rs167.7317.2 52.9%  
Earnings per share (Unadj.) Rs-3.67.8 -46.3%  
Cash flow per share (Unadj.) Rs5.925.1 23.7%  
Dividends per share (Unadj.) Rs4.002.00 200.0%  
Dividend yield (eoy) %1.70.2 754.9%  
Book value per share (Unadj.) Rs372.3274.3 135.7%  
Shares outstanding (eoy) m70.3889.50 78.6%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x1.42.8 50.1%   
Avg P/E ratio x-65.3114.0 -57.2%  
P/CF ratio (eoy) x39.935.7 111.7%  
Price / Book Value ratio x0.63.3 19.5%  
Dividend payout %-110.225.5 -432.1%   
Avg Mkt Cap Rs m16,68080,058 20.8%   
No. of employees `0002.62.5 103.8%   
Total wages/salary Rs m2,3934,341 55.1%   
Avg. sales/employee Rs Th4,535.211,325.8 40.0%   
Avg. wages/employee Rs Th919.81,731.4 53.1%   
Avg. net profit/employee Rs Th-98.2280.1 -35.1%   
INCOME DATA
Net Sales Rs m11,80128,394 41.6%  
Other income Rs m984941 104.6%   
Total revenues Rs m12,78529,334 43.6%   
Gross profit Rs m-8353,965 -21.1%  
Depreciation Rs m6741,540 43.7%   
Interest Rs m751,962 3.8%   
Profit before tax Rs m-6001,403 -42.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m1-168 -0.4%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m-34397 -353.0%   
Profit after tax Rs m-256702 -36.4%  
Gross profit margin %-7.114.0 -50.7%  
Effective tax rate %57.36.9 826.0%   
Net profit margin %-2.22.5 -87.6%  
BALANCE SHEET DATA
Current assets Rs m20,38424,836 82.1%   
Current liabilities Rs m5,02918,993 26.5%   
Net working cap to sales %130.120.6 632.3%  
Current ratio x4.11.3 310.0%  
Inventory Days Days10571 147.6%  
Debtors Days Days135113 118.9%  
Net fixed assets Rs m9,02334,289 26.3%   
Share capital Rs m141895 15.7%   
"Free" reserves Rs m26,05823,651 110.2%   
Net worth Rs m26,19924,546 106.7%   
Long term debt Rs m015,513 0.0%   
Total assets Rs m31,49665,437 48.1%  
Interest coverage x-7.01.7 -406.7%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.40.4 86.3%   
Return on assets %-0.64.1 -14.1%  
Return on equity %-1.02.9 -34.1%  
Return on capital %-2.06.9 -29.0%  
Exports to sales %69.40-   
Imports to sales %00-   
Exports (fob) Rs m8,188NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m8,18815,697 52.2%   
Fx outflow Rs m596735 81.0%   
Net fx Rs m7,59214,962 50.7%   
CASH FLOW
From Operations Rs m-3,2781,871 -175.2%  
From Investments Rs m-2,8605,826 -49.1%  
From Financial Activity Rs m-24-10,157 0.2%  
Net Cashflow Rs m-4,690-2,615 179.4%  

Share Holding

Indian Promoters % 50.1 27.7 180.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 15.1 37.8 39.9%  
FIIs % 3.0 8.6 34.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 31.7 25.9 122.4%  
Shareholders   20,176 56,241 35.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare UNICHEM LAB With:   NATCO PHARMA  PANACEA BIOTECH  WOCKHARDT  ABBOTT INDIA  PLETHICO PHARMA  

Compare UNICHEM LAB With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Extend Gains; Tata Motors & ONGC Climb 5%(12:30 pm)

Share markets in India have extended early morning gains and are presently trading higher. Investors are cautious ahead of the release of Consumer Price Index-based inflation.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

UNICHEM LAB Announces Quarterly Results (1QFY20); Net Profit Up 102.2% (Quarterly Result Update)

Jul 30, 2019 | Updated on Jul 30, 2019

For the quarter ended June 2019, UNICHEM LAB has posted a net profit of Rs 5 m (up 102.2% YoY). Sales on the other hand came in at Rs 2 bn (up 15.4% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

UNICHEM LAB 2018-19 Annual Report Analysis (Annual Result Update)

Jul 4, 2019 | Updated on Jul 4, 2019

Here's an analysis of the annual report of UNICHEM LAB for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of UNICHEM LAB. Also includes updates on the valuation of UNICHEM LAB.

UNICHEM LAB Announces Quarterly Results (4QFY19); Net Profit Up 31.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, UNICHEM LAB has posted a net profit of Rs 37 m (up 31.7% YoY). Sales on the other hand came in at Rs 3 bn (up 35.1% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

What if Indiabulls Housing Finance and Yes Bank Do Not Rebound?(Profit Hunter)

Oct 1, 2019

How long should you wait for fallen blue chips like Yes Bank and Indiabulls Housing Finance to rebound?

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

Foreign Money is Chasing Indian Stocks Once Again(The 5 Minute Wrapup)

Oct 4, 2019

Around Rs 75 billion poured into the Indian stock market in the month of September.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

UNICHEM LAB SHARE PRICE


Oct 14, 2019 01:53 PM

TRACK UNICHEM LAB

  • Track your investment in UNICHEM LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

UNICHEM LAB 5-YR ANALYSIS

COMPARE UNICHEM LAB WITH

MARKET STATS